AI assistant
FATE THERAPEUTICS INC — Director's Dealing 2019
Jan 9, 2019
34091_dirs_2019-01-09_17a5f18c-1956-492b-a5ba-0d26d4612582.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2019-01-07
Reporting Person: Shoemaker Daniel D (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-07 | Common Stock | A | 45000 | $0.00 | Acquired | 135591 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-07 | Stock Option (right to buy) | $16.55 | A | 135000 | Acquired | 2029-01-06 | Common Stock (135000) | Direct |
Footnotes
F1: Award of Restricted Stock Units that vests with respect to 1/3 of the underlying shares on each of January 7, 2020, January 7, 2021, and January 7, 2022. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2019 such that this option is fully exercisable on January 1, 2023.
F3: Not applicable.